Date Title
February 19, 2019
Realm Therapeutics - Second Price Monitoring Extn
RNS Number : 5135Q Realm Therapeutics PLC 19 February 2019   Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.
February 19, 2019
Realm Therapeutics - Price Monitoring Extension
RNS Number : 5128Q Realm Therapeutics PLC 19 February 2019   Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of
February 18, 2019
Realm Therapeutics - Second Price Monitoring Extn
RNS Number : 3387Q Realm Therapeutics PLC 18 February 2019   Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.
February 18, 2019
Realm Therapeutics - Price Monitoring Extension
RNS Number : 3382Q Realm Therapeutics PLC 18 February 2019   Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of
February 18, 2019
Realm Therapeutics - Update on Strategic Review Re-release
RNS Number : 2814Q Realm Therapeutics PLC 18 February 2019   The 'Update on Strategic Review' announcement for Realm Therapeutics released on Friday 15 February 2019 at 6.20pm under RNS No 2805Q has been re-released in the interests of market clarity.   The announcement text is unchanged and is
February 18, 2019
Realm Therapeutics - Block listing Interim Review
RNS Number : 2001Q Realm Therapeutics PLC 18 February 2019   Realm Therapeutics plc Block Listing Interim Review   Pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies Realm Therapeutics plc makes the following update on its block listing:   Date:  18 February 2019   Name of
February 15, 2019
Realm Therapeutics plc ("Realm Therapeutics", "Realm" or the "Company"), Update on Strategic Review, Proposed Assets Disposal, Proposed Adoption of Investing Policy, Proposed AIM Delisting and Notice of General Meeting
Highlights - Proposed disposal of hypochlorous acid (HOCl) Assets to Urgo, U.S. Inc., for $10 million (gross) - Proposed adoption of an Investing Policy and delisting of Ordinary Shares from AIM; ADSs to remain listed for trading on Nasdaq - Circular available on the websites of Realm and the U.S.
February 15, 2019
Realm Therapeutics - Update on Strategic Review
RNS Number : 2805Q Realm Therapeutics PLC 15 February 2019     THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY
December 20, 2018
Realm Therapeutics - Form 8.3 - Realm Therapeutics plc
RNS Number : 1035L Realm Therapeutics PLC 20 December 2018   FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of
December 10, 2018
Realm Therapeutics - Form 8.3 - Realm Therapeutics plc
RNS Number : 9968J Realm Therapeutics PLC 10 December 2018   FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of
Displaying 11 - 20 of 155

Search Investor Relations